Sponsored
- Male
- 13/07/1998
- Followed by 2 people
Recent Updates
- BRIDGE THERAPEUTICS REPORTS PROGRESS AGAINST OPIOID USE DISORDER – DARREN PRINCE TO JOIN COMMERCIAL ADVISORY BOARDNew York, New York – August 29, 2022: Bridge Therapeutics, a developmental stage pharmaceutical company, today reported continued progress towards Phase 3 FDA approval of BT 219, a patented combination of Buprenorphine and Naloxone for Opioid Use Disorder (OUD). Simultaneously, Bridge reported that Darren Prince, an internationally recognized speaker and advisor...0 Comments 0 SharesPlease log in to like, share and comment!
More Stories
Sponsored